庄诗美教授

文章出处: 作者: 发布时间: 2015-03-04 访问次数: 820

    

庄诗美,Ph.D.

教授,博导。科教育部“长江学者”特聘教授,国家杰出青年基金获得者。

联系方式:广州市新港西路135号中山大学生命科学学院贺丹青堂402室,邮编510275

电话: 020-84112164(O),传真: 020-84113469;

Email:zhuangshimei@163.com;LSSZSM@mail.sysu.edu.cn

 

教育及工作经历

 

1981.91987.7  复旦大学上海医学院(原上海医科大学)临床医学系临床医学专业,获医学学士学位。

1987.91992.7  复旦大学上海医学院附属儿科医院,获儿科学医学博士学位。

1995.11999.11  瑞典林雪平(Linkoping)大学医学院,获细胞生物学理学博士学位。

1987.91992.7  复旦大学上海医学院附属儿科医院住院及总住院医生、硕博连读研究生。

1992.71993.5  复旦大学上海医学院医学神经生物学国家重点实验室讲师。

1993.51994.12 荷兰莱登(Leiden)大学分子癌变实验室访问学者。

1995.11999.11 瑞典林雪平(Link?ping)大学医学院博士生。

1999.122000.6 瑞典林雪平大学细胞生物学系博士后。

2000.72002.9  瑞典林雪平大学细胞生物学系助理教授。

2002.10-至今中山大学生命科学学院教授。 

 

研究内容

 

 

1993年以来一直从事癌变机制及信号传导领域的工作,目前的研究重点是非编码RNA在肝癌发生发展中的作用及其分子机制;非编码RNA对细胞信号通路的调控及其机制;非编码RNA的表达调控机制。

庄诗美博士在世界上首次证实 apoptin 通过不依赖p53途径诱导多种人癌细胞株的凋亡,且对抑制细胞凋亡的癌蛋白具有抗性。更重要的 是,apoptin只诱导恶性转化细胞凋亡,而不引起正常细胞死亡,表明apoptin具有被发展为抗癌药物的潜力,尤其是对那些伴随p53功能失活的 肿瘤仍有效。在瑞典进行癌变的分子机制研究期间,尤其系统研究了淋巴瘤发生过程中细胞周期调控因子的基因突变,发现在鼠和人的淋巴瘤 细胞中,对细胞周期具有重要调控作用的Ras/Raf,p53 pRb通道被破坏,同时在世界上首次发现编码p19ARF蛋白的基因缺失,提出p19ARF 能是一个潜在的抑癌因子,目前这一观点已被广泛接受和引用。

 

发表论文

 通讯作者论文:

1. J Cheng, DH Huo, DM Kuang, J Yang, L Zheng*, SM Zhuang*. Human macrophages promote the motility and invasiveness of osteopontin- knockdown tumor cells. Cancer Res 67(11):5141-7, 2007.

2. DM Kuang, Y Wu, N Chen, J Cheng, SM Zhuang*, L Zheng*. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood, 110(2):587-95, 2007.

3. LL Hu, XX Wang, X Chen, J Chang, C Li, Y Zhang, J Yang, W Jiang, SM Zhuang*. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis, 28(8):1740-4, 2007.

4. J Yang, F Zhou, T Xu, H Deng, YY Ge, C Zhang, J Li, SM Zhuang*. Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas. Mutat Res-Fund Mol M, 638(1-2):205-9, 2008.

5H Su, J Zhao, Y Xiong, T Xu, F Zhou, Y Yuan, Y Zhang, S-M Zhuang*. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res-Fund Mol M, 641(1-2): 27-35, 2008.

6. WZ Wang, J Cheng, J Luo, SM Zhuang* Abrogation of G2/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis. FEBS Lett, 582(18):2689-95, 2008.

7. XD Xiong, JH Fang, FE Qiu, J Zhao, J Cheng, Y Yuan, SP Li, SM Zhuang*. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutat Res-Fund Mol M, 643(1-2):70-4, 2008.

8. T Xu, Y Zhu, QK Wei, Y Yuan, F Zhou, YY Ge, JR Yang, H Su, SM Zhuang*. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis, 29(11):2126-31, 2008. (Highly Cited Papers based on ESI)

9. H Su, JR Yang, T Xu, J Huang, L Xu, Y Yuan*, SM Zhuang*. MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69(3):1135-42, 2009. (Highly Cited Papers based on ESI)

10. XD Xiong, FE Qiu, JH Fang, Y Shen, C Liang, W Jiang*, SM Zhuang*. Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. Mutat Res-Fund Mol M, 662(1-2):10-5, 2009.

11. T Xu, Y Zhu, Y Xiong, YY Ge, JP Yun, SM Zhuang*. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology, 50(1):113-21, 2009. (Highly Cited Papers based on ESI; Recommended Article by the Faculty of 1000 Biology)

12. Y Xiong, JH Fang, JP Yun, J Yang, Y Zhang, WH Jia, SM Zhuang*. Effects of microRNA-29 on apoptosis, tumorigenicity and prognosis of hepatocellular carcinoma. Hepatology, 51(3): 836-45, 2010. (Highly Cited Papers based on ESI)

13. C Zeng, R Wang, D Li, XJ Lin, QK Wei, Y Yuan, Q Wang, W Chen, SM Zhuang*. A novel GSK-3β-C/EBPα-miR-122-Insuline-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology, 52(5):1702-12, 2010. (Recommended Article by the Faculty of 1000 Biology)

14. J Luo, J Yang, B-Y Yu, W Liu, M Li, SM Zhuang*. Identification of Siah-interacting protein as a potential regulator of apoptosis and curcumin resistance. Oncogene, 29(48):6357–66, 2010.

15. JH Fang, HC Zhou, C Zeng, J Yang, Y Liu, X Huang, JP Zhang, XY Guan, SM Zhuang*.MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression. Hepatology, 54(5):1729-40, 2011. (Highly Cited Papers based on ESI)

16. Y Zhu, Y Lu, Q Zhang, JJ Liu, TJ Li, JR Yang, C Zeng, SM Zhuang*. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40(10):4615-25, 2012.

17. J Gong, JP Zhang, BKLi, CX Zeng, KYou, MX Chen, Y Yuan*, SM Zhuang*. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 32(25):3071-9, 2013.

18. R Wang, N Zhao, S Li, JH Fang, MX Chen, J Yang, WH Jia, Y Yuan*, SM Zhuang*. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2 and CDC42. Hepatology 58(2):642-53, 2013.

19. JP Zhang, C Zeng, L Xu , J Gong , JH Fang, SM Zhuang.* MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 33(31):4069-76, 2014.

20. N Zhao, R Wang, L Zhou, Y Zhu, J Gong, SM Zhuang*. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer 13(1):35, 2014.

21. YY Ge, Q Shi, ZY Zheng, J Gong, C Zeng, J Yang, SM Zhuang*. MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R. Oncotarget 30;5(15):6218-28, 2014.

22. JJ Liu, XJ Lin, X Yang, L Zhou, S He, SM Zhuang*, J Yang*. A novel     AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res, 42(19):12041-51, 2014.

23. Hui-Chao Zhou, Jian-Hong Fang, Xu Luo, Lei Zhang, Jine Yang, Chong   Zhang, Shi-Mei Zhuang*. Downregulation of MicroRNA-100 Enhances the ICMT-Rac1 Signaling and Promotes Metastasis of Hepatocellular Carcinoma Cells. Oncotarget 5(23):12177-88, 2014.

 

合作者论文:

1.   JR Yang, SM Zhuang, J Zhang*. Impact of translational error-induced and error-free misfolding on the rate of protein evolution. Mol Syst Biol, 6:文献编号421, 2010.

2.   J Hou, L Lin, WP Zhou, ZX Wang, GS Ding, QZ Dong, LX Qin, XB Wu, YY Zheng, Y Yang, W Tian, QA Zhang, CM Wang, QH Zhang, SM Zhuang, LM Zheng, AM Liang, WZ Tao, XT Cao*. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19(2):232-43, 2011. (Highly Cited Papers based on ESI)

3. G Alpini*, S Glaser, JP Zhang, H Francis, Y Han, J Gong, A Stokes, T Francis, N Hughart, L Hubble, SM Zhuang, F Meng*. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol, 55(6):1339-45, 2011.

4.   Q Wang, DC Li, ZF Li, CX Liu, YM Xiao, B Zhang, XD Li, J Zhao, LP Chen, XM Xing, SF Tang, YC Lin, YD Lai, P Yang, JL Zeng, Q Xiao, XW Zeng, ZN Lin, ZX Zhuang, SM Zhuang, W Chen*. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene 29(48):6357-66, 2011.

5. Y Tao, J Ruan, SH Yeh, X Lu, Y Wang, W Zhai, J Cai, S Ling, Q Gong, Z Chong, Z Qu, Q Li, J Liu, J Yang, C Zheng, C Zeng, HY Wang, J Zhang, SH Wang, L Hao, L Dong, W Li, M Sun, W Zou, C Yu, C Li, G Liu, L Jiang, J Xu, H Huang, C Li, S Mi, B Zhang, B Chen, W Zhao, S Hu, SM Zhuang, Y Shen, S Shi, C Brown, KP White, DS Chen, PJ Chen*, CI Wu*. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci USA 108(29):12042-7, 2011.

6.   D Li, X Liu, L Lin, J Hou, N Li, C Wang, P Wang, Q Zhang, P Zhang, W Zhou, Z Wang, G Ding, SM Zhuang, L Zheng, W Tao and X Cao*. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. J Biol Chem 286(42):36677-85, 2011.

7.   JR Yang, BY Liao, SM Zhuang, J Zhang*. Protein misinteraction avoidance causes highly expressed proteins to evolve slowly. Proc Natl Acad Sci USA 109(14):E831-40, 2012. (Highly Cited Papers based on ESI)

8.   J Xu, T Ding, Q He, XJ Yu, WC Wu, WH Jia, JP Yun, Y Zhang, M Shi, CK Shao, WD Pan, XY Yin, J Min, SM Zhuang, L Zheng*. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol 57(2):313-21, 2012.

9.   Q Gong, Y Tao, JR Yang, J Cai, Y Yuan, J Ruan, J Yang, H Liu, W Li, X Lu, SM Zhuang, SM Wang and CI Wu. Identification of medium-sized genomic deletions with low coverage, mate-paired restricted tags. BMC Genomics 14:文献编号51, 2013.

10.       JH, Y Zhou, Y Zheng, J Fan, W Zhou, IOL Ng, H Sun, L Qin, S Qiu, JMF Lee, CM Lo, K Man, Y Yang, Y Yang, Y Yang, Q Zhang, X Zhu, N Li, Z Wang, G Ding, SM Zhuang, L Zheng, X Luo, Y Xie, A Liang, Z Wang, M Zhang, Q Xia, T Liang, Y Yu, X Cao*. Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma. Cancer Cell 25(1):49-63, 2014.

 

获得奖励

 

1. 庄诗美,长江学者特聘教授奖励计划,教育部,2001

2. 庄诗美,杰出青年科学基金项目,国家自然科学基金委,2009

3. 庄诗美,国务院政府特殊津贴,中华人民共和国国务院,2010

4. 庄诗美,国家百千万人才工程及有突出贡献中青年专家,中华人民共和国人力资源和社会保障部,2013

5. 组织免疫微环境调控肝癌进展的新机制,教育部高校科研优秀成果奖(自然科学)一等奖,排名第三,2013年,证书号:2013-028,完成人:郑利民,邝栋明、庄诗美、吴艳、李莲。

6. 组织免疫微环境调控肝癌进展的新机制,广东省科学技术奖自然科学类,一等奖,排名第三,2013年,粤府证:[2014]1401号,完成人:郑利民,邝栋明、庄诗美、吴艳、李莲。

7. 组织免疫微环境促进人肝癌进展的新机制,国家自然科学奖,二等奖,排名第二,2014年,项目完成人:郑利民,庄诗美、邝栋明、吴艳、方坚鸿。